Physiologically based pharmacokinetic model for fluorocarbon elimination after the administration of an octafluoropropane‐albumin microsphere sonographic contrast agent
A physiologically based pharmacokinetic model was developed to evaluate the kinetics of one of the newest sonographic contrast agents available, FS069 or Optison. This material consists of octafluoropropane gas encapsulated in proteinaceous microspheres, injected intravenously for use as a myocardia...
Gespeichert in:
| Veröffentlicht in: | Journal of ultrasound in medicine 1999-01, Vol.18 (1), p.1-11 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 11 |
|---|---|
| container_issue | 1 |
| container_start_page | 1 |
| container_title | Journal of ultrasound in medicine |
| container_volume | 18 |
| creator | Hutter, J C Luu, H M Mehlhaff, P M Killam, A L Dittrich, H C |
| description | A physiologically based pharmacokinetic model was developed to evaluate the kinetics of one of the newest sonographic contrast agents available, FS069 or Optison. This material consists of octafluoropropane gas encapsulated in proteinaceous microspheres, injected intravenously for use as a myocardial contrast agent in humans. This model has six compartments: two lung compartments (alveolar and dead volume), and compartments for the heart, slowly perfused tissue, richly perfused tissue, and gastrointestinal tract. The model was developed to determine the distribution and excretion of the octafluoropropane in the body. Despite the high affinity of octafluoropropane for tissue, the model predicted that nearly 100% of the material would be exhaled from the lungs within 6 min. The model verified the results of a phase I clinical trial with 10 healthy subjects. Ventilation rate was found to play a critical role in the complete excretion of this contrast agent. The physiologically based pharmacokinetic model was a useful tool for evaluating the safety of FS069. This model can be used a basis for developing similar models for other types of contrast agents. |
| doi_str_mv | 10.7863/jum.1999.18.1.1 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69561304</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>69561304</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4361-6b238e7431a1b134eb68f5f2a7348418ace47c27825c7b618d1207a51a0e91333</originalsourceid><addsrcrecordid>eNqFUcuO1DAQjBBoGRbOnJB8QNySdcdO4hzRanlpERzYs9VxOhMvTjzYidDc-AS-g8_iS_AoIzgiWX51dXWpKsueAy8aVYur-3UqoG3bAlQBBTzIdlBVPG9rEA-zHS8blcuybR5nT2K857zk0MiL7KJtq5I3Ypf9-jweo_XO761B546sw0g9O4wYJjT-q51psYZNvifHBh_Y4FYfvMHQ-ZmRs5OdcbHpjsNCgS0jMezTp41L2Ap-YJh2s-DWe0gLZ_r94ye6bk1QNlkTfDyMFIhFP_t9wMOYpho_J5K4MNzTvDzNHg3oIj07n5fZ3ZubL9fv8ttPb99fv77NjRQ15HVXCkWNFIDQgZDU1WqohhIbIZUEhYZkY5IxZWWargbVQ7ICK0BOLQghLrNXG28S-m2luOjJRkPOJdF-jbpuq-Qulwl4tQFP6mOgQR-CnTAcNXB9SkendPQpHQ1Kg4bU8eJMvXYT9X_x5zhS_eW5jjHFMQScjY3_aGtRcVkmmNpg362j4_-m6g93H09PUADiD_rzr9Y</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69561304</pqid></control><display><type>article</type><title>Physiologically based pharmacokinetic model for fluorocarbon elimination after the administration of an octafluoropropane‐albumin microsphere sonographic contrast agent</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Hutter, J C ; Luu, H M ; Mehlhaff, P M ; Killam, A L ; Dittrich, H C</creator><creatorcontrib>Hutter, J C ; Luu, H M ; Mehlhaff, P M ; Killam, A L ; Dittrich, H C</creatorcontrib><description>A physiologically based pharmacokinetic model was developed to evaluate the kinetics of one of the newest sonographic contrast agents available, FS069 or Optison. This material consists of octafluoropropane gas encapsulated in proteinaceous microspheres, injected intravenously for use as a myocardial contrast agent in humans. This model has six compartments: two lung compartments (alveolar and dead volume), and compartments for the heart, slowly perfused tissue, richly perfused tissue, and gastrointestinal tract. The model was developed to determine the distribution and excretion of the octafluoropropane in the body. Despite the high affinity of octafluoropropane for tissue, the model predicted that nearly 100% of the material would be exhaled from the lungs within 6 min. The model verified the results of a phase I clinical trial with 10 healthy subjects. Ventilation rate was found to play a critical role in the complete excretion of this contrast agent. The physiologically based pharmacokinetic model was a useful tool for evaluating the safety of FS069. This model can be used a basis for developing similar models for other types of contrast agents.</description><identifier>ISSN: 0278-4297</identifier><identifier>EISSN: 1550-9613</identifier><identifier>DOI: 10.7863/jum.1999.18.1.1</identifier><identifier>PMID: 9952073</identifier><identifier>CODEN: JUMEDA</identifier><language>eng</language><publisher>Laurel, MD: American Institute of Ultrasound in Medicine</publisher><subject>Adult ; Albumins - pharmacokinetics ; Biological and medical sciences ; Chromatography, Gas ; Contrast Media - pharmacokinetics ; Contrast media. Radiopharmaceuticals ; Echocardiography ; Female ; Fluorocarbons - pharmacokinetics ; General pharmacology ; Humans ; Injections, Intravenous ; Male ; Medical sciences ; Microspheres ; Models, Biological ; Pharmacokinetics. Pharmacogenetics. Drug-receptor interactions ; Pharmacology. Drug treatments</subject><ispartof>Journal of ultrasound in medicine, 1999-01, Vol.18 (1), p.1-11</ispartof><rights>2016 by the American Institute of Ultrasound in Medicine</rights><rights>1999 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4361-6b238e7431a1b134eb68f5f2a7348418ace47c27825c7b618d1207a51a0e91333</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.7863%2Fjum.1999.18.1.1$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.7863%2Fjum.1999.18.1.1$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,4024,27923,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1635042$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9952073$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hutter, J C</creatorcontrib><creatorcontrib>Luu, H M</creatorcontrib><creatorcontrib>Mehlhaff, P M</creatorcontrib><creatorcontrib>Killam, A L</creatorcontrib><creatorcontrib>Dittrich, H C</creatorcontrib><title>Physiologically based pharmacokinetic model for fluorocarbon elimination after the administration of an octafluoropropane‐albumin microsphere sonographic contrast agent</title><title>Journal of ultrasound in medicine</title><addtitle>J Ultrasound Med</addtitle><description>A physiologically based pharmacokinetic model was developed to evaluate the kinetics of one of the newest sonographic contrast agents available, FS069 or Optison. This material consists of octafluoropropane gas encapsulated in proteinaceous microspheres, injected intravenously for use as a myocardial contrast agent in humans. This model has six compartments: two lung compartments (alveolar and dead volume), and compartments for the heart, slowly perfused tissue, richly perfused tissue, and gastrointestinal tract. The model was developed to determine the distribution and excretion of the octafluoropropane in the body. Despite the high affinity of octafluoropropane for tissue, the model predicted that nearly 100% of the material would be exhaled from the lungs within 6 min. The model verified the results of a phase I clinical trial with 10 healthy subjects. Ventilation rate was found to play a critical role in the complete excretion of this contrast agent. The physiologically based pharmacokinetic model was a useful tool for evaluating the safety of FS069. This model can be used a basis for developing similar models for other types of contrast agents.</description><subject>Adult</subject><subject>Albumins - pharmacokinetics</subject><subject>Biological and medical sciences</subject><subject>Chromatography, Gas</subject><subject>Contrast Media - pharmacokinetics</subject><subject>Contrast media. Radiopharmaceuticals</subject><subject>Echocardiography</subject><subject>Female</subject><subject>Fluorocarbons - pharmacokinetics</subject><subject>General pharmacology</subject><subject>Humans</subject><subject>Injections, Intravenous</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Microspheres</subject><subject>Models, Biological</subject><subject>Pharmacokinetics. Pharmacogenetics. Drug-receptor interactions</subject><subject>Pharmacology. Drug treatments</subject><issn>0278-4297</issn><issn>1550-9613</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFUcuO1DAQjBBoGRbOnJB8QNySdcdO4hzRanlpERzYs9VxOhMvTjzYidDc-AS-g8_iS_AoIzgiWX51dXWpKsueAy8aVYur-3UqoG3bAlQBBTzIdlBVPG9rEA-zHS8blcuybR5nT2K857zk0MiL7KJtq5I3Ypf9-jweo_XO761B546sw0g9O4wYJjT-q51psYZNvifHBh_Y4FYfvMHQ-ZmRs5OdcbHpjsNCgS0jMezTp41L2Ap-YJh2s-DWe0gLZ_r94ye6bk1QNlkTfDyMFIhFP_t9wMOYpho_J5K4MNzTvDzNHg3oIj07n5fZ3ZubL9fv8ttPb99fv77NjRQ15HVXCkWNFIDQgZDU1WqohhIbIZUEhYZkY5IxZWWargbVQ7ICK0BOLQghLrNXG28S-m2luOjJRkPOJdF-jbpuq-Qulwl4tQFP6mOgQR-CnTAcNXB9SkendPQpHQ1Kg4bU8eJMvXYT9X_x5zhS_eW5jjHFMQScjY3_aGtRcVkmmNpg362j4_-m6g93H09PUADiD_rzr9Y</recordid><startdate>199901</startdate><enddate>199901</enddate><creator>Hutter, J C</creator><creator>Luu, H M</creator><creator>Mehlhaff, P M</creator><creator>Killam, A L</creator><creator>Dittrich, H C</creator><general>American Institute of Ultrasound in Medicine</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>199901</creationdate><title>Physiologically based pharmacokinetic model for fluorocarbon elimination after the administration of an octafluoropropane‐albumin microsphere sonographic contrast agent</title><author>Hutter, J C ; Luu, H M ; Mehlhaff, P M ; Killam, A L ; Dittrich, H C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4361-6b238e7431a1b134eb68f5f2a7348418ace47c27825c7b618d1207a51a0e91333</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Adult</topic><topic>Albumins - pharmacokinetics</topic><topic>Biological and medical sciences</topic><topic>Chromatography, Gas</topic><topic>Contrast Media - pharmacokinetics</topic><topic>Contrast media. Radiopharmaceuticals</topic><topic>Echocardiography</topic><topic>Female</topic><topic>Fluorocarbons - pharmacokinetics</topic><topic>General pharmacology</topic><topic>Humans</topic><topic>Injections, Intravenous</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Microspheres</topic><topic>Models, Biological</topic><topic>Pharmacokinetics. Pharmacogenetics. Drug-receptor interactions</topic><topic>Pharmacology. Drug treatments</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hutter, J C</creatorcontrib><creatorcontrib>Luu, H M</creatorcontrib><creatorcontrib>Mehlhaff, P M</creatorcontrib><creatorcontrib>Killam, A L</creatorcontrib><creatorcontrib>Dittrich, H C</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of ultrasound in medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hutter, J C</au><au>Luu, H M</au><au>Mehlhaff, P M</au><au>Killam, A L</au><au>Dittrich, H C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Physiologically based pharmacokinetic model for fluorocarbon elimination after the administration of an octafluoropropane‐albumin microsphere sonographic contrast agent</atitle><jtitle>Journal of ultrasound in medicine</jtitle><addtitle>J Ultrasound Med</addtitle><date>1999-01</date><risdate>1999</risdate><volume>18</volume><issue>1</issue><spage>1</spage><epage>11</epage><pages>1-11</pages><issn>0278-4297</issn><eissn>1550-9613</eissn><coden>JUMEDA</coden><abstract>A physiologically based pharmacokinetic model was developed to evaluate the kinetics of one of the newest sonographic contrast agents available, FS069 or Optison. This material consists of octafluoropropane gas encapsulated in proteinaceous microspheres, injected intravenously for use as a myocardial contrast agent in humans. This model has six compartments: two lung compartments (alveolar and dead volume), and compartments for the heart, slowly perfused tissue, richly perfused tissue, and gastrointestinal tract. The model was developed to determine the distribution and excretion of the octafluoropropane in the body. Despite the high affinity of octafluoropropane for tissue, the model predicted that nearly 100% of the material would be exhaled from the lungs within 6 min. The model verified the results of a phase I clinical trial with 10 healthy subjects. Ventilation rate was found to play a critical role in the complete excretion of this contrast agent. The physiologically based pharmacokinetic model was a useful tool for evaluating the safety of FS069. This model can be used a basis for developing similar models for other types of contrast agents.</abstract><cop>Laurel, MD</cop><pub>American Institute of Ultrasound in Medicine</pub><pmid>9952073</pmid><doi>10.7863/jum.1999.18.1.1</doi><tpages>11</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0278-4297 |
| ispartof | Journal of ultrasound in medicine, 1999-01, Vol.18 (1), p.1-11 |
| issn | 0278-4297 1550-9613 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_69561304 |
| source | MEDLINE; Access via Wiley Online Library |
| subjects | Adult Albumins - pharmacokinetics Biological and medical sciences Chromatography, Gas Contrast Media - pharmacokinetics Contrast media. Radiopharmaceuticals Echocardiography Female Fluorocarbons - pharmacokinetics General pharmacology Humans Injections, Intravenous Male Medical sciences Microspheres Models, Biological Pharmacokinetics. Pharmacogenetics. Drug-receptor interactions Pharmacology. Drug treatments |
| title | Physiologically based pharmacokinetic model for fluorocarbon elimination after the administration of an octafluoropropane‐albumin microsphere sonographic contrast agent |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T17%3A45%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Physiologically%20based%20pharmacokinetic%20model%20for%20fluorocarbon%20elimination%20after%20the%20administration%20of%20an%20octafluoropropane%E2%80%90albumin%20microsphere%20sonographic%20contrast%20agent&rft.jtitle=Journal%20of%20ultrasound%20in%20medicine&rft.au=Hutter,%20J%20C&rft.date=1999-01&rft.volume=18&rft.issue=1&rft.spage=1&rft.epage=11&rft.pages=1-11&rft.issn=0278-4297&rft.eissn=1550-9613&rft.coden=JUMEDA&rft_id=info:doi/10.7863/jum.1999.18.1.1&rft_dat=%3Cproquest_cross%3E69561304%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=69561304&rft_id=info:pmid/9952073&rfr_iscdi=true |